Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | AR | P10275 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.61 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL6 | P05231 | 1/20 | 0.57 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.57 |
| ▸ | GLUL | P15104 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Valerate Acetate SCHEMBL14339603 | 1.00 | PGR (0.72) | PGRHIF1ANR3C1LMNACYP3A4 | |
| Prednisolone Valerate Acetate SCHEMBL375318 | 1.00 | PGR (0.72) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL391631 | 0.94 | PGR (0.74) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL5602245 | 0.93 | PGR (0.80) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL5602237 | 0.93 | PGR (0.80) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL730945 | 0.92 | HIF1A (0.79) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL11436847 | 0.92 | PGR (0.76) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL10940343 | 0.92 | PGR (0.69) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL10940339 | 0.92 | PGR (0.69) | PGRHIF1ANR3C1LMNACYP3A4 | |
| SCHEMBL2299113 | 0.91 | PGR (0.78) | PGRHIF1ANR3C1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023160631-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 中南大学湘雅医院 | 2023-08-31 | — | — | WO | claimed |
| EP-1097712-B1 | STEROID-CONTAINING CATAPLASMS AND PROCESS FOR PRODUCING THE SAME | HISAMITSU PHARMACEUTICAL CO (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6432431-B1 | GEL PATCHES CONTAINING CROTAMITON, CURING AGENTS, NONIONIC SURFACTANTS AND STEROLS ON NON-WOVEN FABRIC SUPPORTS HAVING AIR PERMEABILITY AND STORGE STABILITY; USED FOR ECZEMA, DERMATITIS AND ATOPIC DISEASES | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2002-08-13 | — | — | US | claimed |
| EP-1097712-A1 | STEROID-CONTAINING CATAPLASMS AND PROCESS FOR PRODUCING THE SAME | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2001-05-09 | — | — | EP | claimed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| US-20210386758-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | PRIMUS PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11179465-B2 | Topical compositions comprising a corticosteroid | PRIMUS PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210069214-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | ENCORE DERMATOLOGY, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2021046444-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | ENCORE DERMATOLOGY, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| US-10905697-B2 | Topical formulations comprising a steroid | ENCORE DERMATOLOGY, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3267978-B1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID | PROMIUS PHARMA LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200405733-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | ENCORE DERMATOLOGY, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| JP-2001072603-A | EXTERNAL PREPARATION COMPOSED OF PREDNISOLONE ACETATE VALERATE AND BASIC LOCAL ANESTHETIC | ZERIA PHARMACEUT CO LTD | 2001-03-21 | — | — | JP | disclosed |
| EP-1077066-A1 | PREVENTIVES/REMEDIES FOR SKIN DISEASES | Showa Denko Kabushiki Kaisha (JP) | 2001-02-21 | — | — | EP | disclosed |
| EP-0241050-B1 | AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATION CONTAINING THE ABSORPTION PROMOTERS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1992-10-14 | — | — | EP | disclosed |
| US-5021408-A | Administering antiinflammatory agents | JOUVEINAL S.A. (FR) | 1991-06-04 | — | — | US | disclosed |
| US-4933331-A | ANTIINFLAMMATORY AGENTS | JOUVEINAL, S.A. (FR) | 1990-06-12 | — | — | US | disclosed |
| US-4882359-A | USED WITH DRUGS | HISAMITSU PHARMACEUTICAL CO., LTD. (JP) | 1989-11-21 | — | — | US | disclosed |
| WO-1987006226-A2 | AZACYCLOALKANE DERIVATIVES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS THE EFFECTIVE INGREDIENT AND EXTERNAL PREPARATIONS CONTAINING THE ABSORPTION PROMOTERS | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1987-10-22 | — | — | WO | disclosed |
| EP-0241050-A2 | Azacycloalkane derivatives, absorption promoters containing the derivatives as the effective ingredient and external preparation containing the absorption promoters | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069214-A1 | TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID FOR THE TREATMENT OF PSORIASIS IN PEDIATRIC PATIENTS | TSLP, IL17A, IL5 | PGR 420/4885HIF1A 1427/4885NR3C1 7/4885 |
| US-11179465-B2 | Topical compositions comprising a corticosteroid | NR5A1, NR3C1, CYP17A1 | PGR 442/4885HIF1A 4032/4885NR3C1 2/4885 |
| US-20210386758-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | PGR 233/4885HIF1A 2508/4885NR3C1 11/4885 |
| US-20200405733-A1 | TOPICAL FORMULATIONS COMPRISING A STEROID | NR5A1, CYP17A1, TSLP | PGR 233/4885HIF1A 2508/4885NR3C1 11/4885 |
| US-10905697-B2 | Topical formulations comprising a steroid | NR5A1, CYP17A1, TSLP | PGR 233/4885HIF1A 2508/4885NR3C1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.